Common asthma medicine can speed up Covid-19 recovery by three days – study gazettelive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazettelive.co.uk Daily Mail and Mail on Sunday newspapers.
Date Time
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19
Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the UK’s PRINCIPLE trial in 1,779 participants.
Early treatment with inhaled budesonide shortens recovery time by a median of three days in patients with COVID-19 who are at higher risk of more severe illness and are treated in the community, finds Oxford University’s Platform Randomised Trial of Interventions against COVID-19 in Older People (PRINCIPLE) trial.
An inhaled, widely available, asthma drug shortens recovery time in people with coronavirus who have not been admitted to hospital, a new study suggests.
British patients will be able to access the first ever at-home Covid-19 treatment after the NHS approved budesonide for use on a “case-by-case” basis among older adults in the community, which means that GPs will be able to prescribe it to their patients.
Researchers say the discovery is a “significant milestone” for the pandemic, and that the drug, budesonide, is effective as a treatment at home and during the early stages of the illness.
Early treatment with the medication shortens recovery time by a median average of three days in those with Covid-19 who are at higher risk of more severe illness and are treated in the community, according to the research.
Asthma drug reduces Covid-19 recovery time in those not admitted to hospital leaderlive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderlive.co.uk Daily Mail and Mail on Sunday newspapers.